Skip to main content

Advertisement

Table 3 Associations between MMR gene polymorphisms and platinum-based chemotherapy toxicity in the 220 NSCLC patients

From: Association between DNA mismatch repair gene polymorphisms and platinum-based chemotherapy toxicity in non-small cell lung cancer patients

Toxicity Gene SNP Additive model Dominant model Recessive model
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Overall MSH2 rs6544991 1.18 (0.77–1.79) 0.447 1.39 (0.76–2.55) 0.290 1.02 (0.44–2.33) 0.973
MSH3 rs6151627 1.20 (0.77–1.86) 0.419 1.49 (0.83–2.65) 0.181 0.77 (0.27–2.17) 0.618
  rs6151670 1.14 (0.73–1.76) 0.572 1.37 (0.76–2.45) 0.293 0.75 (0.27–2.13) 0.593
  rs7709909 1.21 (0.79–1.87) 0.380 1.51 (0.84–2.71) 0.163 0.83 (0.31–2.19) 0.703
MSH5 rs707939 0.45 (0.28–0.73) 0.001 0.42 (0.23–0.76) 0.004 0.27 (0.09–0.84) 0.023
  rs805304 1.66 (1.04–2.65) 0.034 2.21 (1.19–4.09) 0.012 1.21 (0.44–3.34) 0.716
Hematologic MSH2 rs6544991 1.01 (0.64–1.61) 0.957 0.97 (0.50–1.87) 0.919 1.12 (0.45–2.77) 0.805
MSH3 rs6151627 1.55 (0.96–2.50) 0.074 2.38 (1.23–4.60) 0.010 0.75 (0.23–2.44) 0.635
  rs6151670 1.42 (0.88–2.29) 0.153 2.05 (1.07–3.93) 0.032 0.75 (0.23–2.43) 0.630
  rs7709909 1.55 (0.97–2.49) 0.067 2.38 (1.23–4.64) 0.010 0.87 (0.30–2.58) 0.808
MSH5 rs707939 0.68 (0.41–1.12) 0.128 0.66 (0.35–1.28) 0.219 0.50 (0.16–1.54) 0.225
  rs805304 1.37 (0.83–2.27) 0.223 1.99 (1.01–3.90) 0.047 0.60 (0.16–2.20) 0.436
Gastrointestinal MSH2 rs6544991 1.56 (0.90–2.69) 0.113 2.98 (1.20–7.40) 0.019 0.88 (0.28–2.76) 0.827
MSH3 rs6151627 0.63 (0.33–1.20) 0.161 0.54 (0.24–1.19) 0.128 0.66 (0.14–3.02) 0.592
  rs6151670 0.67 (0.35–1.27) 0.220 0.59 (0.27–1.32) 0.199 0.64 (0.14–2.94) 0.568
  rs7709909 0.62 (0.33–1.18) 0.145 0.55 (0.25–1.20) 0.132 0.58 (0.13–2.63) 0.481
MSH5 rs707939 0.46 (0.24–0.88) 0.020 0.44 (0.20–0.96) 0.038 0.21 (0.03–1.65) 0.139
  rs805304 1.64 (0.90–2.97) 0.105 1.86 (0.83–4.20) 0.133 1.85 (0.56–6.14) 0.314
  1. OR odds ratio, 95% CI 95% confidence interval; other abbreviations as in Table 1